JN Biosciences LLC

Dr. J Yun Tso is a Cofounder and Managing Partner of JN Biosciences LLC and has thirty years of antibody drug development experience.  Prior to JN Biosciences, Dr. Tso was Director, Oncology at Protein Design Labs, Inc., which was later acquired by Abbvie.  During his seventeen year tenure at Protein Design Labs, he created several humanized antibodies against cancer targets as well as molecules that are pivotal for T-cell functions.  Dr. Tso’s group studied the efficacy of these antibodies through in vitro and in vivo characterizations.  He brought two humanized antibodies into the clinic: apolizumab, which is directed towards HLA-DR expressed on lymphomas and lymphocytic leukemias, and visilizumab, which is a novel anti-CD3 antibody that inhibits activated, but not resting, T cells.  In addition, Dr. Tso is a co-inventor of Emplicity™ (humanized anti-CS1 antibody approved for marketing in the U.S. for treatment of multiple myeloma) and Zinbryta™ (humanized anti-CD25 antibody approved for marketing in the U.S. for treatment of relapsing multiple sclerosis). Dr. Tso received his Ph.D. degree in Biochemistry from Purdue University, and was a post-doctoral fellow at Cornell University and Stanford University.  He has authored 47 articles in peer-reviewed journals and is a co-inventor on 44 issued U.S. patents.

Click here to go back to Management.